John H. Stone

Active 1989–2025

Also published as
John H Stone
210
Papers
47,296
Citations
106
h-index
205
i10-index

Citations

Citations per year for John H. Stone1978: 2 citations1990: 3 citations1993: 2 citations1994: 2 citations1995: 1 citations1996: 3 citations1997: 7 citations1998: 1 citations1999: 4 citations2000: 5 citations2001: 16 citations2002: 25 citations2003: 35 citations2004: 28 citations2005: 58 citations2006: 72 citations2007: 65 citations2008: 81 citations2009: 71 citations2010: 149 citations2011: 176 citations2012: 250 citations2013: 290 citations2014: 329 citations2015: 391 citations2016: 400 citations2017: 360 citations2018: 314 citations2019: 1,229 citations2020: 1,334 citations2021: 1,604 citations2022: 932 citations2023: 792 citations2024: 1,342 citations2025: 665 citations2026: 8 citations1979–1989: no citations, so these years are not shown1991–1992: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,119 citing papers, 22.3% of this breakdownUnited Kingdom: 803 citing papers, 8.5% of this breakdownItaly: 599 citing papers, 6.3% of this breakdownChina: 596 citing papers, 6.3% of this breakdownGermany: 505 citing papers, 5.3% of this breakdownFrance: 504 citing papers, 5.3% of this breakdownJapan: 480 citing papers, 5.1% of this breakdownNetherlands: 360 citing papers, 3.8% of this breakdownCanada: 343 citing papers, 3.6% of this breakdownSpain: 333 citing papers, 3.5% of this breakdownAustralia: 217 citing papers, 2.3% of this breakdownSweden: 183 citing papers, 1.9% of this breakdown
0%22.3%Other 25.8%

Fields

  • Medicine88%
  • Immunology and Microbiology5.6%
  • Biochemistry, Genetics and Molecular Biology3.9%
  • Neuroscience0.5%
  • Computer Science0.3%
  • Engineering0.3%
  • Other1.4%

Topics

  • Vasculitis and related conditions10%
  • IgG4-Related and Inflammatory Diseases5.8%
  • Otitis Media and Relapsing Polychondritis3.8%
  • Systemic Lupus Erythematosus Research3.2%
  • COVID-19 Clinical Research Studies3.2%
  • Rheumatoid Arthritis Research and Therapies2.7%
  • Other71.3%

Coauthors

All papers

Open in search
  1. Trial of Tocilizumab in Giant-Cell Arteritis

    Authors: , , , , , , , , , , , , , , , - New England Journal of Medicine 2017 cited by 1,375

  2. Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2010 cited by 2,726

  3. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Amy S. Turner, Reem A. Mustafa - Arthritis & Rheumatology 2021 cited by 628

  4. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Amy S. Turner, Reem A. Mustafa - Arthritis & Rheumatology 2021 cited by 649

  5. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease

    Authors: , , , , , , , , , , , , , , , , , , , - Annals of the Rheumatic Diseases 2019 cited by 739

  6. IgG4-related disease: an update on pathophysiology and implications for clinical care

    Authors: , - Nature Reviews Rheumatology 2020 cited by 414

  7. IgG4-Related Disease

    Authors: , , - New England Journal of Medicine 2012 cited by 2,597

  8. Consensus statement on the pathology of IgG4-related disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ji Kon Ryu, Takako Saeki, Dushyant V. Sahani, Thomas C. Smyrk, James R. Stone, Masayuki Takahira, George Webster, Motohisa Yamamoto, Giuseppe Zamboni, Hisanori Umehara, John H. Stone - Modern Pathology 2012 cited by 2,577

  9. The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4‐Related Disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Arthritis & Rheumatology 2019 cited by 658

  10. Rituximab for IgG4-related disease: a prospective, open-label trial

    Authors: , , , , , , , , , - Annals of the Rheumatic Diseases 2015 cited by 709

  11. IgG4-related disease

    Authors: , , , - The Lancet 2014 cited by 1,200

  12. International Consensus Guidance Statement on the Management and Treatment of IgG4‐Related Disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Tooru Shimosegawa, Hiroki Takahashi, Masayuki Takahira, Atsushi Tanaka, Mark Topazian, Hisanori Umehara, George Webster, Thomas E. Witzig, Motohisa Yamamoto, Wen Zhang, T. Chiba, John H. Stone - Arthritis & Rheumatology 2015 cited by 1,051

  13. Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Annals of the Rheumatic Diseases 2020 cited by 185

  14. A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome

    Authors: , , , , , , , , , , , , , , , , , , - JCI Insight 2022 cited by 130

  15. Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , John H. Stone - New England Journal of Medicine 2013 cited by 727

  16. Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis

    Authors: , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2020 cited by 187

  17. Clonal expansion of CD4+ cytotoxic T lymphocytes in patients with IgG4-related disease

    Authors: , , , , , , , , , , , , , , , - Journal of Allergy and Clinical Immunology 2016 cited by 416

  18. Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts

    Authors: , , , , , - Annals of the Rheumatic Diseases 2019 cited by 413

  19. B lymphocytes directly contribute to tissue fibrosis in patients with IgG4-related disease

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Allergy and Clinical Immunology 2019 cited by 152

  20. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I

    Authors: , , , , , , , , , , , , , - Arthritis & Rheumatism 2007 cited by 2,077

  21. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Tomas G. Neilan, Cory A. Perugino, Sebastian Unizony, Deborah Collier, Mark Matza, Janeth M Yinh, Kathryn Bowman, Eric A. Meyerowitz, Amna Zafar, Zsófia D. Drobni, Marcy B. Bolster, Minna J. Kohler, Kristin M. D’Silva, Jonathan Dau, Megan M. Lockwood, Caroline Cubbison, Brittany Weber, Michael K. Mansour - New England Journal of Medicine 2020 cited by 1,435

  22. Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis

    Authors: , , , , , , , , , , , , , , , , , , , - Annals of the Rheumatic Diseases 2016 cited by 231

  23. Diagnosis and management of ANCA-associated vasculitis

    Authors: , , , , - The Lancet 2024 cited by 175

  24. Management of IgG4-related disease

    Authors: , - The Lancet Rheumatology 2019 cited by 183